Drug name - Viibryd
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7834020 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(3 months ago) | |
| US8673921 | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(3 months ago) | |
| CN100384841C | ALLERGAN | 1 - [4 - (5-Cyanoindol-3-Group) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph |
Jun, 2022
(3 months ago) | |
| CN101139345A | ALLERGAN | Polymorphic Forms Of 1-4-(5-Cyanoindol-3-Group) Butyl-4-(2-Carbamoylbenzofuran-5-Group) Piperazine Hydrochloride |
Jun, 2022
(3 months ago) | |
| CN1516699A | ALLERGAN | 1 - [4 - (5-Cyanoindol-3-Group) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph |
Jun, 2022
(3 months ago) | |
| CN101139345B | ALLERGAN | 1 - [4 - (5-Indole-3-Yl) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph |
Jun, 2022
(3 months ago) | |
| EP1397357B1 | ALLERGAN | Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride |
Jun, 2022
(3 months ago) | |
| EP1397357A2 | ALLERGAN | Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride |
Jun, 2022
(3 months ago) | |
| EP1397357B9 | ALLERGAN | Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride |
Jun, 2022
(3 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7834020
(Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(2 months from now) | |
|
US8193195
(Pediatric) | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(2 months from now) | |
|
US8236804
(Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(2 months from now) | |
|
US8673921
(Pediatric) | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(2 months from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET;ORAL | Prescription |
| 20MG | TABLET;ORAL | Prescription |
| 40MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.